Summary Globally, acne vulgaris was responsible for 4·96 million (95% UI 2·98–7·85) DALYs in 2019. Of these, 3·52 million (2·11–5·64) DALYs occurred in those ages 15–49 years old.
Definition Acne vulgaris (or acne) is a chronic inflammatory disease of the pilosebaceous unit associated with an increase in sebum secretion (ICD-10: L70, excluding L70.4).
Total sources | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Incidence | 0 | |||||||||||
Prevalence | 90 | |||||||||||
Remission | 0 | |||||||||||
Causes of death | 0 | |||||||||||
Other | 15 | |||||||||||
Table 1:
Total sources used in GBD 2019 estimation
What is new in GBD 2019?
- •Instead of DisMod-MR, MR-BRT was used to adjust outpatient data (and data that were not based on physical exams) toward the level of other prevalence datapoints, which were more representative of the general population.
- •Data for both sexes combined and large age categories were assigned to sex-specific and more fine-grained age categories.
- •New data from Poland (2015–2017) and USA claims data (2015–2016) were incorporated into the model.
Prevalence
|
Incidence
|
Deaths
|
YLLs
|
YLDs
|
DALYs
|
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Cases
(millions) |
Rate (per 100 000)
|
Cases
(millions) |
Rate (per 100 000)
|
Deaths
(millions) |
Rate (per 100 000)
|
YLLs
(millions) |
Rate (per 100 000)
|
YLDs
(millions) |
Rate (per 100 000)
|
DALYs
(millions) |
Rate (per 100 000)
|
|
2019 | ||||||||||||
Both Sexes | 231 (208 to 255) |
3073·3 (2761·6 to 3403·1) |
117 (103 to 134) |
1585·9 (1384·8 to 1812·2) |
-– |
-– |
-– |
-– |
4·96 (2·98 to 7·85) |
65·9 (39·6 to 104·4) |
4·96 (2·98 to 7·85) |
65·9 (39·6 to 104·4) |
Females | 129 (116 to 141) |
3485·9 (3143·8 to 3846·4) |
65·0 (57·2 to 73·7) |
1796·0 (1570·8 to 2045·9) |
-– |
-– |
-– |
-– |
2·75 (1·65 to 4·34) |
74·5 (44·8 to 117·9) |
2·75 (1·65 to 4·34) |
74·5 (44·8 to 117·9) |
Males | 103 (91·8 to 114) |
2675·9 (2392·9 to 2978·7) |
52·4 (45·9 to 59·9) |
1384·9 (1206·7 to 1586·9) |
-– |
-– |
-– |
-– |
2·21 (1·32 to 3·51) |
57·6 (34·4 to 91·6) |
2·21 (1·32 to 3·51) |
57·6 (34·4 to 91·6) |
Percentage change 2010-19 | ||||||||||||
Both Sexes | 8·2% (7·8 to 8·7) |
4·1% (3·6 to 4·6) |
9·8% (9·0 to 10·6) |
4·9% (4·2 to 5·6) |
-– |
-– |
-– |
-– |
8·2% (7·4 to 8·9) |
4·1% (3·3 to 4·8) |
8·2% (7·4 to 8·9) |
4·1% (3·3 to 4·8) |
Females | 7·5% (6·9 to 8·1) |
3·3% (2·7 to 3·9) |
9·3% (8·3 to 10·3) |
4·3% (3·5 to 5·2) |
-– |
-– |
-– |
-– |
7·4% (6·5 to 8·3) |
3·3% (2·4 to 4·1) |
7·4% (6·5 to 8·3) |
3·3% (2·4 to 4·1) |
Males | 9·2% (8·5 to 9·8) |
5·2% (4·4 to 5·8) |
10·4% (9·5 to 11·3) |
5·6% (4·7 to 6·4) |
-– |
-– |
-– |
-– |
9·1% (8·1 to 10·2) |
5·1% (4·0 to 6·1) |
9·1% (8·1 to 10·2) |
5·1% (4·0 to 6·1) |
Numbers in parentheses are 95% uncertainty intervals. |
Table 2:
Global prevalence, incidence, deaths, YLLs, YLDs, and DALYs in counts and age-standardised rates for both sexes combined, females, and males, 2019, with percentage change between 2010 and 2019
Deaths | YLLs | YLDs | DALYs | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
1990 | -- | -- | 42nd | 95th | ||||||||
2010 | -- | -- | 37th | 87th | ||||||||
2019 | -- | -- | 37th | 83rd | ||||||||
Table 3:
Rank among Level 3 causes for global deaths, YLLs, YLDs, and DALYs in 1990, 2010, and 2019, for both sexes combined

Figure 1:
Composition of DALYs by constituent sequelae YLDs for both sexes combined, 2019


Figure 2:
Age-standardised DALY rates for each location by SDI, both sexes combined, 2019

Figure 3:
Composition of DALYs by YLLs and YLDs, age group, and sex, 2019


Figure 4:
Age-standardised DALY rates (per 100 000) by location, both sexes combined, 2019